Abstract
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in recent years because of the improved understanding of the disease biology and the development of novel targeted therapies. In patients with indications for initiating treatment, the selection of treatment should be based on the disease stage, patient's age and overall fitness (performance status and comorbid conditions), and cytogenetic abnormalities. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / standards*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / analysis
-
Biomarkers, Tumor / genetics
-
Bone Marrow / pathology
-
Disease-Free Survival
-
Drug Resistance, Neoplasm / genetics
-
Hematopoietic Stem Cell Transplantation / methods
-
Hematopoietic Stem Cell Transplantation / standards*
-
Humans
-
Immunophenotyping
-
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
-
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
-
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
-
Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
-
Lymph Nodes / cytology
-
Lymph Nodes / pathology
-
Lymphocytes / pathology
-
Medical Oncology / methods
-
Medical Oncology / standards*
-
Mutation
-
Neoplasm Recurrence, Local / epidemiology
-
Neoplasm Recurrence, Local / therapy*
-
Neoplasm Staging
-
Organizations, Nonprofit / standards
-
Prognosis
-
Remission Induction / methods
-
Transplantation, Homologous / standards
-
United States / epidemiology